Labcorp stock gains after Q2 2026 earnings and investor day guidance
Published on 09/16/2026 at 19:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Labcorp Holdings Inc. stock (ISIN US50540R4092) closed at USD 323.97 on the New York Stock Exchange on September 15, 2026, gaining 2.75% from the previous close of USD 315.31 as investors digested Q2 2026 results and fresh guidance from management. According to Yahoo Finance on September 15, 2026, the move leaves Labcorp shares close to the upper end of their recent trading range.
Q2 2026 earnings and updated growth targets
Labcorp’s most recent reported figures come from its second quarter 2026, when the company delivered revenues of USD 3.73 billion, up 5.8% year on year, in line with analysts’ expectations. As TradingView reported on September 16, 2026, the Q2 2026 performance represented the slowest revenue growth and weakest full year guidance update among Labcorp’s close diagnostics peers, even though the company achieved a decent beat versus analysts’ full year EPS guidance.
Management used its appearance at Morgan Stanley’s 24th Annual Global Healthcare Conference on September 15, 2026 to sharpen medium term growth targets. According to Choicestock on September 16, 2026, Labcorp now aims for revenue growth of 5 to 8 percent in 2026, coupled with double digit net income margins, supported by an expansion in AI driven specialty testing and drug development services. That 5 to 8 percent target sits modestly above the 5.8% revenue increase achieved in Q2 2026, signalling management’s expectation of a slightly stronger growth run rate in the second half of the year.
Investor day and strategy through 2029
Beyond the current year, Labcorp is positioning its diagnostics and drug development businesses for structural growth. As Yahoo Finance reported on September 16, 2026, the company held an investor day on September 10, 2026, where executives highlighted investments in artificial intelligence, specialty testing and data driven clinical development to drive growth through 2029. The strategic focus is on higher margin testing niches and supporting 90% of FDA approved drugs with Labcorp’s development services, a level that the company already reached in 2023.
For shareholders, the combination of Q2 2026 revenue growth of 5.8% and management’s new 5 to 8 percent growth band for 2026 serves as a key benchmark. It suggests that, if Labcorp can lift revenue growth by roughly 0.2 to 2.2 percentage points versus the latest quarterly trend while maintaining double digit net income margins, EPS could compound at a healthy pace. However, Choicestock also noted on September 16, 2026 that the lack of detailed quarterly guidance and consensus comparison data leaves some investors cautious about the reliability of these targets.
Analyst targets and valuation context
Analyst houses have responded to Labcorp’s execution and updated strategy with measured optimism. According to Yahoo Finance on September 15, 2026, UBS maintained its Buy rating on Labcorp and raised its 12 month price target from USD 361 to USD 380 on September 11, 2026. That upward revision of USD 19 implies potential upside of roughly 17.2% from the September 15, 2026 closing price of USD 323.97 if UBS’s scenario plays out, and it underscores confidence in the company’s ability to deliver against its mid single digit to high single digit growth framework.
Valuation metrics point to a share price that is not far from estimated fair value. As Simply Wall St noted on September 16, 2026, Labcorp’s share price of USD 323.97 sits only slightly below a widely followed fair value estimate of USD 337.75, suggesting limited margin for error if growth or margins disappoint. The same analysis highlighted a 24.8% 90 day share price return and a 28.7% year to date share price return, along with a three year total shareholder return of 63.9% compared with 19.4% over the past year, indicating that longer term holders have enjoyed a substantial payoff.
Stock performance, range and investor perspective
The latest share price reaction came against a backdrop of strong recent performance and a rising trading range. Per Nasdaq data reported on Yahoo Finance on September 15, 2026, Labcorp stock closed at USD 323.97 on the New York Stock Exchange after trading between USD 314.09 at the open and an intraday high that approached its recent 52 week range. The portal’s performance overview shows Labcorp with a 30.09% year to date total return as of September 15, 2026, compared with 10.81% for the S and P 500, and a 1 year return of 18.83% versus 14.67% for the index. That outperformance, especially the roughly 19.3 percentage point gap in year to date returns, indicates that investors have been willing to pay up for Labcorp’s diagnostics and drug development exposure.
At the current USD 323.97 level, Labcorp trades between the 52 week low of USD 293.00 and a recent range high of around USD 385.00, leaving a buffer of about USD 30.97 above the low and approximately USD 61.03 below the high. According to Yahoo Finance on September 15, 2026, the current price is close to the average of USD 343.31 implied by its recent trading band, reinforcing the picture of a stock that has already priced in a significant portion of its near term growth story.
Closing price and market data
Labcorp stock (NYSE: LH) closed at USD 323.97 on the New York Stock Exchange on September 15, 2026, up 2.75% from the prior close of USD 315.31 in USD terms. As of that date, the shares were trading well above their 52 week low of USD 293.00 but still below a recent high near USD 385.00, while delivering a year to date total return of 30.09% compared with 10.81% for the S and P 500, per data from Nasdaq and Yahoo Finance.
Key data on Labcorp stock
- Company: Labcorp Holdings Inc.
- ISIN: US50540R4092
- Ticker: LH
- Trading venue: New York Stock Exchange
- Price (as of September 15, 2026, 4:00 PM): 323.97 USD
- Market capitalization: 30.09% year to date return versus 10.81% for S and P 500 (as of September 15, 2026)
- Sector / Industry: Health Care - Diagnostics and research
- Index membership: S and P 500
